our pipeline

The science of Tumor Treating Fields has the potential to extend beyond glioblastoma. Tumor Treating Fields has shown a consistent anti-mitotic effect in our preclinical and clinical research over the last 18 years.

We believe we have gained a deep understanding of the underlying mechanism of action and the multiple pathways through which Tumor Treating Fields exert their effects within dividing cancer cells. Our research shows that Tumor Treating Fields can have an anti-mitotic effect in 18 different solid tumor types in culture and in eight in vivo tumor models, including some of the most aggressive forms of cancer. We are committed to advancing the science of Tumor Treating Fields across a broad spectrum of solid tumors and bringing our treatment to cancer patients who can benefit from our therapy.

Novocure clinical pipeline

as of May 2018

Pre-clinical
Phase II
Phase III
FDA Approved
Recurrent Glioblastoma
Newly Diagnosed Glioblastoma
Brain Metastasis
Non-small Cell Lung Cancer
Pancreatic Cancer
Ovarian Cancer
Mesothelioma
Trial ongoing
Trial complete

we also have pre-clinical data for Tumor Treating Fields in these areas:

Pre-clinical

  • breast cancer
  • cervical cancer
  • colorectal carcinoma
  • ependymoma
  • gastric adenocarcinoma
  • gliosarcoma
  • hepatocellular carcinoma
  • malignant melanoma
  • medulloblastoma
  • meningioma
  • renal adenocarcinoma
  • small cell lung cancer
  • urinary transitional cell carcinoma

clinical trials

Novocure continues to test Tumor Treating Fields against a broad range of solid tumor types.

We sponsor clinical trials of Tumor Treating Fields in several cancer types. For more information on our ongoing clinical trials, visit novocuretrial.com and clinicaltrials.gov.

LUNAR

Cancer type: Non-small cell lung cancer (Phase 3 pivotal)

Protocol number: NCT02973789

About NSCLC: Lung cancer is the most common cause of cancer-related death worldwide, and non-small cell lung cancer accounts for approximately 85% of all lung cancers. Approximately 214,000 new cases of NSCLC are diagnosed in the U.S. each year, approximately 350,000 new cases are diagnosed annually in Europe, and approximately 95,000 new cases are diagnosed annually in Japan. Of the 214,000 Americans diagnosed with lung cancer annually, only 18% are alive five years later.

Learn more about LUNAR.

Read More

METIS

Cancer type: Brain metastases from non-small cell lung cancer (Phase 3 pivotal)

Protocol number: NCT02831959

About brain metastases: Metastatic cancer is cancer that has spread from the place where it first started to another place in the body. In metastasis, cancer cells break away from the primary cancer, travel through the blood or lymph system, and form new, metastatic tumors in other parts of the body. The exact incidence of brain metastases is unknown, but it has been estimated that 98,000 to 170,000 new cases are diagnosed in the United States each year. Brain metastases occur in roughly 15% of all cancer patients, and we believe that approximately 40% of brain metastases are a result of NSCLC.

Learn more about METIS.

Read More

PANOVA 3

Cancer type: Pancreatic cancer

Protocol number: NCT03377491

About pancreatic cancer: Pancreatic cancer is one of the most lethal cancers and is the third most frequent cause of death from cancer in the United States. While overall cancer incidence and death rates are declining, the incidence and death rates for pancreatic cancer are increasing. The incidence of pancreatic cancer is 54,000 new cases annually in the United States, approximately 130,000 new cases annually in Europe, and approximately 39,000 new cases annually in Japan. Pancreatic cancer is the only major cancer with a five-year relative survival rate in the single digits, at just 8 percent.

Learn more about PANOVA 3

Read More

STELLAR

Cancer type: Mesothelioma (Phase 2 pilot)

Protocol number: NCT02397928

About mesothelioma: Malignant mesothelioma is a rare thoracic solid tumor cancer that occurs in approximately 3,000 patients in the United States annually. Asbestos exposure has been strongly associated with the development of mesothelioma, which may occur many years later. Mesothelioma has a very poor prognosis, with a median overall survival of approximately 12 months in most reported studies.

Learn more about STELLAR.

Read More

additional research

Additional investigator-sponsored trials are also ongoing. For the most up-to-date clinical trial information, including protocol details, please visit the U.S. National Institutes of Health’s website at clinicaltrials.gov.

This information is for medical, and scientific and educational purposes only. Tumor Treating Fields is experimental for the treatment of patients with brain metastases, ovarian carcinoma, pancreatic adenocarcinoma, mesothelioma and non-small cell lung cancer. Tumor Treating Fields has not been approved by the U.S. Food and Drug Administration for commercial use in these indications. Limited by federal law to investigational use only.